nih glp 1 Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025) GLP-1 Agonists For Obesity In

AOD-9604 failed Phase 2 not due to safety concerns but because the magnitude of fat loss versus placebo, while statistically significant, was too modest to meet the efficacy threshold for a standalone obesity treatment

This is significant because visceral fat drives insulin resistance, inflammation, and cardiovascular risk to a degree that subcutaneous fat does not

Programs like TrimRX can create personalized plans that combine medication with the tools and guidance you need to build lasting, healthy habits

GLP-1 medications like Wegovy may help women manage polycystic ovary syndrome (PCOS), a hormonal condition linked to symptoms such as acne, excessive hair growth, weight gain and fertility issues

Accessed October 5, 2023